Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
|Videos|September 28, 2021
Current Research Underway in CTCL Treatment
Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, explains what research is underway in the advanced cutaneous T cell lymphoma field that she is currently keeping an eye on.
Advertisement
Pharmacy Times interviewed Lauren C. Pinter-Brown, MD, FACP, professor in the Department of Dermatology and the Department of Medicine in the Division of Hematology and Oncology at UCI Health and Chao Family Comprehensive Cancer Center, on her recent presentation at the Society of Hematologic Oncology Annual Meeting 2021 conference on the treatment of advanced cutaneous T cell lymphoma (CTCL) in 2021.
During this discussion, Pinter-Brown explains what research is underway in the CTCL field that she is currently keeping an eye on.
Advertisement
Related to this article
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-fourths of treated patients.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Butter, Beef Tallow, and LDL: Where Dietary Guidelines Diverge
2
Pharmacists Key to Lp(a) Counseling and Lipid Optimization
3
Why Patients Fear Statins Will Affect Their Memory
4
Precision in Practice: Biomarker Testing and Treatment Selection in Primary Advanced or Recurrent Endometrial Cancer
5